A discussion on recent data updates from the REDUCE-IT trial, and their practical implications for physicians managing cardiovascular risk.
A discussion on recent data updates from the REDUCE-IT trial, and their practical implications for physicians managing cardiovascular risk.
FDA Approves Aprocitentan For Treatment of Uncontrolled High Blood Pressure
March 20th 2024Aprocitentan (TRYVIO) from pharmaceutical company Idorsia demonstrated statistically significant and clinically meaningful reductions in blood pressure in combination with other antihypertensive therapies.